This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.

With one exception, the investigational oral drug laquinimod was more effective than placebo, and possibly better than interferon-beta-1a (Avonex), in reducing clinically relevant aspects of multiple sclerosis (MS), a researcher said here.

But that exception was a doozy: on the phase III BRAVO trial's primary efficacy endpoint, annualized relapse rate, laquinimod failed to show significantly better efficacy than placebo, reported Timothy Vollmer, MD, of the University of Colorado in Denver.

According to the two-year trial's prespecified method for measuring annualized relapse rates in the primary analysis, laquinomid produced a rate of 0.28 relapses, versus 0.34 for placebo (risk ratio 0.82, 95% CI 0.66 to 1.02, P=0.075).

On the other hand, when the data were adjusted for baseline clinical factors associated with relapse rate that were imbalanced between treatment groups in the randomized trial -- also planned in the BRAVO protocol -- annualized relapse rates rose enough in the placebo group to give laquinimod a statistically significant advantage (0.37 placebo, 0.29 laquinimod, P=0.03).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1735

Who is online

This site does not offer, or claim to offer, medical, legal, or professional advice.
All treatment decisions should always be made with the full knowledge of your physicians.
This is MS does not create, endorse, or republish any content.
All postings are the responsibility of the poster. All logos and trademarks in this site are property of their respective owners. All users must respect our rules for intellectual property rights.